Scope of the
Report
The report titled “Global PAH Market: Trends and Opportunities (2015-2019)”, analyzes the potential opportunities and significant trends in the global Pulmonary Arterial Hypertension (PAH) market. The market size and forecast in value terms for global PAH market has been provided for the period 2010 to 2019, considering 2014 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2015 to 2019. Over the next five years, Global PAH market revenue is forecasted to remain stable due to patent expiries and launch of new drugs.
The report titled “Global PAH Market: Trends and Opportunities (2015-2019)”, analyzes the potential opportunities and significant trends in the global Pulmonary Arterial Hypertension (PAH) market. The market size and forecast in value terms for global PAH market has been provided for the period 2010 to 2019, considering 2014 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2015 to 2019. Over the next five years, Global PAH market revenue is forecasted to remain stable due to patent expiries and launch of new drugs.
Request a sample
of this report @ http://www.orbisresearch.com/contacts/request-sample/185293
.
The report provides detailed analysis of the global PAH market sizing and
growth by type for the period 2010-2014. The market is further segment by drug
mechanism and different dosage forms. The analysis of PAH individual drugs
sales are also provided in the report.
The report profiles key market players such as Actelion Ltd., United
Therapeutics Ltd. and SteadyMed Ltd. on the basis of attributes such as company
overview, recent developments, strategies adopted by the market leaders to
ensure growth, sustainability, financial overview and recent developments.
Purchase a copy of
Global Pulmonary Arterial Hypertension (PAH) Market visit @ http://www.orbisresearch.com/contact/purchase/185293
For more information contact sales@orbisresearch.com .
Company Coverage
Actelion Limited
United Therapeutics Limited
SteadyMed Limited
Actelion Limited
United Therapeutics Limited
SteadyMed Limited
PAH Drug Mechanism
Endothelin Receptor Antagonists (ERA)
PDE 5 Inhibitors
Prostacyclins
sGC Stimulator
Endothelin Receptor Antagonists (ERA)
PDE 5 Inhibitors
Prostacyclins
sGC Stimulator
Executive Summary
Pulmonary Arterial Hypertension (PAH) is a disease in which high blood pressure occurs in the right ventricle of the heart and the pulmonary arteries that supply blood to the lungs. The increase in pressure is caused by constriction and narrowing of the small pulmonary arteries. In 2005, standard of care was characterized by intravenous treatment aimed at reducing symptoms, not addressing root cause. Now, new treatments are available that go beyond symptom management to treat the underlying cause of PAH. With advancement in the standard of care, patients are able to maintain active lifestyles with a reduced risk of serious heart events associated with PAH.
Pulmonary Arterial Hypertension (PAH) is a disease in which high blood pressure occurs in the right ventricle of the heart and the pulmonary arteries that supply blood to the lungs. The increase in pressure is caused by constriction and narrowing of the small pulmonary arteries. In 2005, standard of care was characterized by intravenous treatment aimed at reducing symptoms, not addressing root cause. Now, new treatments are available that go beyond symptom management to treat the underlying cause of PAH. With advancement in the standard of care, patients are able to maintain active lifestyles with a reduced risk of serious heart events associated with PAH.
In 2001, the US Food and Drug Administration (FDA) approved Tracleer as
the treatment for patients with PAH. Actelion develop the Tracleer and the
sales of Tracleer grew rapidly due to a high patient switch over from off-label
drugs to Tracleer. Tracleer, the major revenue generating drug of the PAH
market is expected to go off patent by 2015.
Despite an increase in per-member-per-year spend from 2013 to 2014; trend
for medications used to treat pulmonary hypertension is expected to be sluggish
again in 2015, chiefly because of the market saturation of generic sildenafil.
The global PAH market is expected to achieve highest sales till now in the year
2017 due to imminent release of the PAH drug called Uptravi (Selexipag) in
2016, which is anticipated to potentially drive the growth of the total market
till 2019. Popularity of combinational therapies is also likely to drive the
market in the aforementioned period.
Browse Complete Report @ http://www.orbisresearch.com/reports/index/global-pulmonary-arterial-hypertension-pah-market-trends-and-opportunities-2015-2019
.
Some points from TOC:
1. Executive Summary
2. Pulmonary Arterial Hypertension
(PAH): An Introduction
2.1 Definition of PAH
2.2 Classification of PAH
2.3 Causes of PAH
2.4 Who gets PAH?
2.5 How Serious is PAH?
2.6 Symptoms of PAH
2.7 Diagnosis of PAH
2.8 Treatment of PAH
2.8.1 Medications
2.8.2 Surgery
2.8.3 Lifestyle Changes
2.9 How does it affect?
2.1 Definition of PAH
2.2 Classification of PAH
2.3 Causes of PAH
2.4 Who gets PAH?
2.5 How Serious is PAH?
2.6 Symptoms of PAH
2.7 Diagnosis of PAH
2.8 Treatment of PAH
2.8.1 Medications
2.8.2 Surgery
2.8.3 Lifestyle Changes
2.9 How does it affect?
About Us:
Orbis Research (orbisresearch.com) is a
single point aid for all your market research requirements. We have vast
database of reports from the leading publishers and authors across the globe.
We specialize in delivering customized reports as per the requirements of our
clients. We have complete information about our publishers and hence are sure
about the accuracy of the industries and verticals of their specialization.
This helps our clients to map their needs and we produce the perfect required
market research study for our clients.
Contact
Information:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1
(214) 884-6817; +9164101019
No comments:
Post a Comment